U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701083) titled 'A Study of Eloralintide (LY3841136) in Healthy Participants' on July 09.
Brief Summary: The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions. Participation in this study will last about 13 weeks, including screening, inpatient treatment, and follow-up.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Eloralintide
Administered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by HT Digital Content Services with permission from Health Daily Digest....